Last $109.31 USD
Change Today +0.32 / 0.29%
Volume 101.6K
TFX On Other Exchanges
New York
As of 4:15 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

teleflex inc (TFX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/14 - $111.24
52 Week Low
09/26/13 - $80.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TELEFLEX INC (TFX)

Related News

No related news articles were found.

teleflex inc (TFX) Related Businessweek News

No Related Businessweek News Found

teleflex inc (TFX) Details

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company operates in three segments: Vascular, Anesthesia/Respiratory, and Surgical. It offers vascular access products that facilitate various critical care therapies, including the administration of intravenous medications and other therapies, the measurement of blood pressure, and taking of blood samples through a single puncture site; anesthesia products, such as airway management products under the LMA and Rusch brands, and pain management products under the Arrow brand; respiratory care products, such as oxygen therapy, aerosol therapy, spirometry, and ventilation management products under the Hudson RCI brand; and specialty products, including interventional access products, and products provided to specialty market customers. The company also provides surgical products, such as ligation and closure products used in surgical procedures; access ports for use in minimally invasive surgical procedures; fluid management products for use in chest drainage; and reusable hand-held instruments for general and specialty surgical procedures under the Deknatel, Pilling, Pleur-evac, Taut, and Weck brands. In addition, it offers cardiac care products comprising diagnostic catheters, including thermodilution and wedge pressure catheters; angiographic and therapeutic delivery catheters; sheaths for femoral and trans-radial aortic access, and intra-aortic balloons; and capital equipment, such as intra-aortic balloon pumps under the Arrow brand. Further, the company provides original equipment manufacturing and development services. Teleflex Incorporated offers its products to hospitals and healthcare providers in approximately 150 countries through its direct sales force and distributors. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.

11,400 Employees
Last Reported Date: 02/24/14
Founded in 1943

teleflex inc (TFX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $826.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.5K
Executive Vice President and President of Ame...
Total Annual Compensation: $427.1K
Compensation as of Fiscal Year 2013.

teleflex inc (TFX) Key Developments

Teleflex Incorporated Announces Results of New Peer-Reviewed Study Involving the ARROW PICC with Chlorag ard Technology

Teleflex Incorporated has announced results of a new peer-reviewed study involving the ARROW(R) PICC with Chlorag(+) ard(R) Technology, published in the Fall 2014 issue of the Journal of the Association for Vascular Access (JAVA). The ARROW(R) PICC with Chlorag(+) ard(R) Technology is the world's first and only antimicrobial and antithrombogenic PICC. The research, using the ARROW(R) PICC with Chlorag(+) ard(R) Technology, determined that this kind of Peripherally Inserted Central Catheter (PICC) was associated with a nearly nine-fold drop in the rate of Central Line-Associated Bloodstream Infections (CLABSIs). The peer-reviewed study was conducted at Sharp Chula Vista Medical Center (SCVMC) in Chula Vista, Calif. The study was undertaken in part because the medical center's CLABSI rate had remained above the national benchmark, despite comprehensive efforts to prevent these potentially deadly infections. Use of an antimicrobial catheter in such circumstances is recommended by the CDC and the Infusion Nurses Society. In the study, concurrent data was collected from 260 patients who received the ARROW(R) PICC with Chlorag(+) ard(R) Technology. That data was then compared to retrospective data for 257 patients who had only received unprotected PICCs during the previous year. The results of the study showed a clear, positive impact from the ARROW(R) PICC with Chlorag(+) ard(R) Technology. The 257 subjects in the non-interventional group had eight CLABSIs and an infection rate of 4.18/1,000 line days. The 260 subjects in the interventional group had only one CLABSI and an infection rate of 0.47 infections/1,000 line days. In addition, a financial analysis showed that the ARROW(R) PICC with Chlorag(+) ard(R) Technology reduced costs associated with CLABSIs. Using the device enabled the hospital to avoid seven CLABSIs during the six-month study period. Conservatively assuming a treatment cost of $16,500 per infection, researchers calculated that SCVMC saved $115,500 during the study period -- an amount that includes the added cost for the preventive PICCs. The study author was Glenell Rutkoff, MSN, RN, CGRN, Manager Ambulatory and Ancillary Services at SCVMC.

Teleflex Incorporated Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 10:00 AM

Teleflex Incorporated Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Benson F. Smith, Chairman, Chief Executive Officer, President and Member of Non-Executive Equity Awards Committee.

Teleflex Incorporated Announces Newly Published Clinical Study Demonstrates That the Accuracy of the ARROW(R) VPS G4(TM) Vascular Positioning System

Teleflex Incorporated announced that a newly published clinical study demonstrates that the accuracy of the ARROW(R) VPS G4(TM) Vascular Positioning System, with placements of peripherally inserted central catheters (PICCs), can eliminate the use of confirmatory chest X-rays. The peer-reviewed study, titled "Successfully Eliminating Chest Radiography by Replacing It with Dual Vector Technology and an Algorithm for PICC Placement," appeared in the June 2014 issue of the Journal of the Association for Vascular Access (JAVA). The prospective, non-randomized research showed that the VPS G4(TM) System achieved 100% accuracy in placement of PICCs in an initial group of patients with normal sinus rhythm (normal heartbeat). When used in this study the device was also found to be useful in several patients who had atrial fibrillation -- that is, an irregular heartbeat. Because the system enables accurate catheter placement, the study concludes, confirmatory chest X-rays can be eliminated, when a steady Blue Bullseye is illuminated, which in turn reduces radiation exposure for patients, speeds the delivery of therapy and lowers direct costs. The VPS G4(TM) System combines intravascular electrocardiogram (ECG), intravascular Doppler ultrasound and a unique software algorithm to accurately place catheter tips in the lower 1/3 of the Superior Vena Cava (SVC) at the heart's Cavo-Atrial Junction (CAJ). The VPS G4(TM) Device is FDA cleared to eliminate chest X-ray in adult patients, when a steady Blue Bullseye is achieved. In the study, the VPS G4(TM) System was used with 31 patients selected from the PICC patient population at Presence Saint Joseph Medical Center (Joliet, Ill.). For purposes of the study, placement with the system was considered accurate if the result obtained with a steady Blue Bullseye was confirmed by a subsequent chest X-ray. The study results are important for several reasons: Reduced radiation exposure. If accurate placements can be made without relying on a confirmatory X-ray, patients are spared the exposure to the associated radiation. Avoidance of treatment delays. At many hospitals, it can take up to several hours to obtain a confirmatory X-ray, which delays treatment, and then have the X-ray read by a radiologist, which further delays treatment. Reduced costs. Confirmatory X-rays, which are read by radiologists, add costs. So do malpositioned catheter tips, which require adjustment of the line position. The positioning system can eliminate confirmatory chest X-rays in most cases and also minimizes catheter malpositions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TFX:US $109.31 USD +0.32

TFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ansell Ltd A$19.37 AUD -0.11
Hill-Rom Holdings Inc $43.92 USD +0.05
PerkinElmer Inc $44.35 USD +0.05
Sirona Dental Systems Inc $77.22 USD -0.41
STERIS Corp $56.40 USD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation TFX Industry Range
Price/Earnings 30.0x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 27.6x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELEFLEX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at